#Chemiluminescence Immunoassay Growth

[omshinde5145]

Chemiluminescence Immunoassay Market Sluggish Growth Rate Foreseen by 2024–2030

The Chemiluminescence Immunoassay Market was valued at USD 12.6 billion in 2023 and will surpass USD 20.2 billion by 2030; growing at a CAGR of 7.0% during 2024 - 2030. Chemiluminescence Immunoassay is a biochemical method used to detect and measure the concentration of various analytes in blood or other bodily fluids. It is widely used for diagnosing diseases by identifying specific antibodies, hormones, or proteins associated with various medical conditions. CLIA offers a highly sensitive, specific, and automated approach to diagnostics, making it a preferred choice in laboratories and hospitals.

The principle behind CLIA is based on the use of chemiluminescent molecules that emit light during the immunological reaction. The amount of emitted light correlates with the presence of the target analyte, allowing accurate quantification.

Key Market Players

Several key players are contributing to the competitive landscape of the global CLIA market. Some of the prominent companies include:

Siemens Healthineers

Abbott Laboratories

Roche Diagnostics

Danaher Corporation

BioMérieux SA

Thermo Fisher Scientific Inc.

Read More about Sample Report: https://intentmarketresearch.com/request-sample/chemiluminescence-immunoassay-market-3625.html

Key Trends Driving Growth in the CLIA Market

Rise in Chronic Diseases: The growing incidence of chronic diseases such as cardiovascular diseases, diabetes, and cancer has boosted the demand for reliable diagnostic tools like CLIA. Early detection and monitoring of these diseases are critical to improving patient outcomes, creating significant demand for CLIA testing solutions.

Technological Advancements in Diagnostics: Continuous innovations in immunoassay platforms, including the integration of automation and artificial intelligence, have enhanced the efficiency and accuracy of CLIA tests. Automation reduces manual errors, speeds up the testing process, and facilitates large-scale testing, which is crucial for diagnostic laboratories.

Growing Focus on Infectious Disease Detection: The COVID-19 pandemic underscored the importance of rapid and accurate diagnostic testing. CLIA played a pivotal role in detecting viral antibodies and monitoring immune responses. With the threat of emerging infectious diseases, there is an ongoing need for rapid, sensitive, and scalable diagnostic solutions.

Increasing Preference for Point-of-Care Testing: The shift towards decentralized healthcare has led to a rise in demand for point-of-care (POC) diagnostics, where CLIA-based POC tests are gaining traction. Portable CLIA analyzers enable quick and accurate testing at the patient’s bedside or in remote locations, reducing the need for hospital visits.

Expansion in Research and Development: Pharmaceutical and biotechnology companies are heavily investing in R&D to develop new CLIA-based tests for various applications, from oncology to infectious disease diagnostics. This has led to the expansion of the market with new products, addressing previously unmet diagnostic needs.

Challenges in the CLIA Market

Despite its robust growth, the CLIA market faces several challenges, including:

High Equipment Costs: The initial setup costs for CLIA analyzers and related instruments can be prohibitively high for smaller laboratories and clinics, limiting market penetration in low-resource settings.

Skilled Workforce Requirements: Proper execution of CLIA tests requires highly skilled personnel. A shortage of trained professionals in certain regions may slow down the widespread adoption of CLIA technology.

Regulatory Compliance: The regulatory landscape for diagnostic testing is complex, with various approval processes differing by region. Ensuring compliance with local and international regulations can pose challenges for market players.

Regional Market Insights

North America: Dominates the global CLIA market, thanks to its well-established healthcare infrastructure, the presence of major market players, and the growing prevalence of chronic diseases. The United States, in particular, accounts for a significant market share due to high healthcare expenditure and ongoing technological advancements.

Europe: The European CLIA market follows closely behind North America, driven by the increasing demand for diagnostic tools, especially in countries like Germany, France, and the UK.

Asia-Pacific: This region is anticipated to experience the fastest growth, fueled by the rising healthcare needs of a growing population, increased investment in healthcare infrastructure, and the expanding middle class in countries like China, India, and Japan. Additionally, improving awareness of early disease detection in these markets further boosts demand for CLIA-based diagnostics.

Latin America and Middle East & Africa: These regions are gradually adopting CLIA technology, driven by the need for advanced diagnostic solutions. However, the market growth in these areas is slower due to limited resources and the high costs associated with the technology.

These companies are continuously investing in R&D, strategic partnerships, and product launches to strengthen their positions in the market.

Ask for Customization Report: https://intentmarketresearch.com/ask-for-customization/chemiluminescence-immunoassay-market-3625.html

Future Outlook and Opportunities

The future of the Chemiluminescence Immunoassay market looks promising, with ample opportunities for growth. The increasing demand for precision medicine, advancements in molecular diagnostics, and the growing focus on preventive healthcare are expected to create significant expansion opportunities.

Personalized Diagnostics: As the healthcare industry moves towards personalized medicine, CLIA technology will play a vital role in developing tailored diagnostics that can cater to individual patient needs.

Emerging Applications: Beyond infectious disease and chronic condition diagnostics, CLIA holds potential in emerging fields such as pharmacogenomics, environmental testing, and food safety, offering diverse growth avenues.

Conclusion

The Chemiluminescence Immunoassay market is poised for continued growth, driven by the increasing demand for efficient diagnostic solutions, technological advancements, and rising awareness about early disease detection. Despite challenges related to costs and regulatory hurdles, the market presents immense opportunities for innovation, especially in personalized medicine and emerging diagnostic applications. As healthcare continues to evolve, CLIA will remain a critical tool in shaping the future of diagnostics.

[global-research-report]

Empowering Healthcare Providers with Precision Blood Screening Tools

Blood Screening Industry Overview

The global blood screening market size is expected to reach USD 6.62 billion by 2030, registering a CAGR of 11.9% from 2025 to 2030, according to a new report by Grand View Research, Inc. The growth of the market is attributed to the increase in screening of donor and continuous technological advancement by the market players. Demand for blood screening tests is increasing continuously due to increasing donation, rising awareness about transfusion-transmitted diseases, and technological developments in the industry. Furthermore, governments of various countries are in process to mandates testing all donated blood for several viruses.

Thorough screening is necessary for all donated blood to ensure that recipients receive the safest products. As of 2015, such testing consists of screening for red cell antibodies, and the infectious diseases agents: HIV-1, HIV-2, hepatitis virus, West Nile Virus (WNV), Human T-Lymphotropic Virus (HTLV) T. Cruzi, and T. pallidum (syphilis). The result of all these assays must be negative for blood donation.

Gather more insights about the market drivers, restrains and growth of the Blood Screening Market

Technological developments increase the sensitivity and efficiency of the tests. For instance, in 2016, the U.S. FDA approved the Procleix Zika virus assay from Hologic, Inc. and Grifols to screen donated blood. Furthermore, the U.S. FDA approved next-generation sequencing (NGS) technology in 2013. The technology is cheaper and faster than previous DNA analysis methods.

Browse through Grand View Research's Clinical Diagnostics Industry Research Reports.

The global body fluid collection and diagnostics market size was estimated at USD 34.35 billion in 2024 and is projected to grow at a CAGR of 6.6% from 2025 to 2030. 

The global genetic testing market size was estimated at USD 11.71 billion in 2024 and is projected to grow at a CAGR of 22.5% from 2025 to 2030.

Blood Screening Market Segmentation

Grand View Research has segmented global blood screening market report based on technology, product, and region:

Blood Screening Technology Outlook (Revenue, USD Million, 2018 - 2030)

Nucleic Acid Amplification Test (NAT)

ELISA

Chemiluminescence Immunoassay (CLIA & EIA )

Next Generation Sequencing (NGS)

Western Blotting (WB)

Blood Screening Product Outlook (Revenue, USD Million, 2018 - 2030)

Reagent

Instrument

Blood Screening Regional Outlook (Revenue, USD Million, 2018 - 2030)

North America

US

Canada

Mexico

Europe

UK

Germany

France

Italy

Spain

Norway

Denmark

Sweden

Asia Pacific

India

Japan

China

South Korea

Australia

Thailand

Latin America

Brazil

Argentina

Middle East and Africa (MEA)

Saudi Arabia

South Africa

UAE

Kuwait

Key Companies profiled:

Abbott

Danaher Corporation (Beckman Coulter)

Becton Dickinson and Company

Bio-Rad Laboratories, Inc.

Hoffman-La Roche Ltd.

Grifols, S.A.

Ortho-Clinical Diagnostics, Inc.

Siemens Healthcare GmbH

Thermo Fisher Scientific, Inc.

SOFINA s.a (Biomerieux)

Key Blood Screening Company Insights

Some of the key companies in the market include Bio-Rad Laboratories, Inc., Hoffman-La Roche Ltd., Grifols, S.A., and others. These companies adopt strategies such as strategic collaborations to enhance innovation, mergers, and acquisitions to expand capabilities, and new product launches to address evolving healthcare needs, ensuring competitiveness and a strong market presence.

Abbott manufactures specialized medical equipment that may utilize Blood Screening components for durability and lightweight properties. Beyond blood screening, Abbott operates in various segments, including laboratory diagnostics, cardiovascular devices, diabetes care, and nutrition products, thereby enhancing its portfolio and addressing diverse healthcare needs.

Bio-Rad Laboratories, Inc. develops diagnostic instruments that may incorporate Blood Screening materials for enhanced performance and reliability in relation to Blood Screening. The company also engages in other segments, such as quality control products, gene expression analysis, and protein purification, positioning itself as a leader in both research and clinical settings.

Recent Developments

In May 2023, Siemens Healthineers launched two new analyzers, the Atellica HEMA 570 and Atellica HEMA 580, designed for high-volume hematology testing, crucial for blood screening. These advanced devices can streamline the complete blood count (CBC) process, offering rapid results and improved workflow efficiency. With the ability to process up to 120 tests per hour, these analyzers can address the growing demand for timely diagnostics in critical care settings.

Order a free sample PDF of the Blood Screening Market Intelligence Study, published by Grand View Research.

[market-insider]

Immunoprotein Diagnostic Testing Market Analysis: Comprehensive Overview of Market Size, Share, Growth

The global immunoprotein diagnostic testing market size is estimated to reach USD 14.86 billion in 2030 and is projected to grow at a CAGR of 7.7% from 2024 to 2030. This growth can be attributed to the rising incidence of chronic diseases. According to American Heart Association’s 2017 statistics, nearly 790,000 people experience heart attack every year in the U.S. In addition, stroke is responsible for 1 in every 20 deaths in the U.S. Hence, WHO is also taking initiatives to reduce the risk of cardiovascular diseases. As a result of the aforementioned factors, the demand for immunoprotein diagnostics is expected to rise in order to facilitate rapid diagnosis.

Immunoprotein Diagnostic Testing Market Report Highlights

Infectious disease testing held largest market share in 2023 owing to the increasing prevalence of infectious diseases and high applications of immunoprotein tests

Enzyme-based immunoassays dominated the market in 2023 due to their frequent usage and availability of large number of products that possess this technology

Chemiluminescence assay is anticipated to witness highest growth over the forecast period due to its high sensitivity and specificity

North America dominated the market in 2023 due to rising prevalence of cancer & increase in mortality due to cancer-related diseases and favorable healthcare reimbursement scenario in the U.S.

For More Details or Sample Copy please visit link @: Immunoprotein Diagnostic Testing Market Report

According to WHO, nearly 1.69 million deaths due to lung cancer were registered in 2015 throughout the world. Hence, fast and accurate diagnosis of such chronic diseases has become important to reduce the high mortality rate. Immunoprotein diagnostic devices and reagents have proved to be highly effective in rapidly detecting chronic diseases.

Technological advancements in the field of immunoprotein diagnostics have led to introduction of novel products. For instance, LIAISON XL, manufactured by DiaSorin, is a fully automated chemiluminescence analyzer that facilitates complete sample processing. It also measures and evaluates testing samples, thereby, enhancing the efficiency and throughput of the system.

List of major companies in the Immunoprotein Diagnostic Testing Market

Agilent Technologies, Inc.

Danaher Corporation

Thermo Fisher Scientific Inc.

PerkinElmer Inc.

Bio-Rad Laboratories, Inc.

Aurora Biomed Inc.

Tecan Trading AG

Promega Corporation

Charles River Laboratories

Creative Biolabs.

For Customized reports or Special Pricing please visit @: Immunoprotein Diagnostic Testing Market Analysis Report

We have segmented the global immunoprotein diagnostic testing market report based on test, technology, material, fluid, application and region.

[industrynewsupdates]

Nurse Call Systems Market Key Companies, Growth and Forecast Report, 2030

The global nurse call systems market size was valued at USD 1.7 billion in 2022 and is expected to expand at a compound annual growth rate (CAGR) of 12.11% from 2023 to 2030. 

The growing need for a diverse and integrated platform that increases the preference for mobility aids are driving the market. Medicare decides to refund schemes based on quality and outcome rather than quantity owing to the rising healthcare cost. Medicare estimates that current reimbursement practices are costing an additional USD 2.1 billion and expects to curtail this by using technology-focused healthcare. With this change in reimbursement policies, hospitals and other healthcare facilities are trying to streamline their workflow processes by adopting technology-oriented nurse call systems.

Nurse call systems enable reliable and flexible communication between the patient and the caregiver. Increasing patient numbers in healthcare facilities and the introduction of advanced ways to expand communication, workflow, and management to provide quality patient care are fueling the market growth. The market is primarily driven by technological advancements that have allowed players to create innovative devices. For instance, in December 2019, Tunstall Group launched Tunstall Carecom, a wireless and digital nurse call system.

Gather more insights about the market drivers, restrains and growth of the Nurse Call Systems Market

Blood Screening Market Report Highlights

• The reagent segment accounted for the largest revenue share of around 73.0% in 2022 and is expected to grow at the fastest CAGR of 12.0% over the forecast period.

• North America dominated the market and accounted for the largest revenue share of 39.0% in 2022 owing to the presence of key industry players, increased adoption of the blood screening process, stringent FDA regulations for transfusion, rising infectious disease prevalence, and greater patient affordability are responsible for maintaining its position during the forecast period.

• Asia Pacific is expected to grow at the fastest CAGR of 13.5% over the forecast period owing to increasing awareness about blood donation, rising patient affordability, and the focus of key industry players on emerging countries in the region.

Browse through Grand View Research's Medical Devices Industry Research Reports.

• The global emergency medical services product market size was valued at USD 22.5 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 6.4% from 2024 to 2030.

• The global scanning electron microscopes market size was valued at USD 4.34 billion in 2023 and is expected to grow at a compound annual growth rate (CAGR) of 8.6% from 2024 to 2030. 

Blood Screening Market Segmentation

Grand View Research has segmented the blood screening market by product, technology, and region:

Blood Screening Technology Outlook (Revenue, USD Million, 2018 - 2030)

• Nucleic Acid Amplification Test (NAT)

• ELISA

• Chemiluminescence Immunoassay (CLIA) and Enzyme Immunoassay (EIA)

• Next Generation Sequencing

• Western Blotting

Blood Screening Product Outlook (Revenue, USD Million, 2018 - 2030)

• Reagent

• Instrument

Blood Screening Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

o U.S.

o Canada

• Europe

o UK

o Germany

o France

o Italy

o Spain

o Sweden

o Norway

o Denmark

• Asia Pacific

o Japan

o China

o India

o Australia

o Thailand

o South Korea

• Latin America

o Brazil

o Mexico

o Argentina

• Middle East and Africa

o Saudi Arabia

o South Africa

o UAE

o Kuwait

Order a free sample PDF of the Nurse Call Systems Market Intelligence Study, published by Grand View Research.

[credenceresearchdotblog]

The Carcinoembryonic Antigen Market is projected to grow from USD 1235 million in 2024 to an estimated USD 3522.944 million by 2032, with a compound annual growth rate (CAGR) of 14% from 2024 to 2032.The global Carcinoembryonic Antigen (CEA) market has been experiencing significant growth, driven by advancements in cancer diagnostics, increased prevalence of cancer worldwide, and the growing awareness of the role of biomarkers in early cancer detection. CEA is a glycoprotein involved in cell adhesion and is commonly used as a tumor marker in cancer diagnostics, particularly for colorectal cancer. This article provides an in-depth analysis of the CEA market, exploring key drivers, restraints, opportunities, and trends shaping its future trajectory.

Browse the full report at https://www.credenceresearch.com/report/carcinoembryonic-antigen-cea-market

Market Definition and Scope

Carcinoembryonic Antigen (CEA) is a biomarker that is frequently measured in blood samples to monitor cancer progression, especially in patients with colorectal, breast, pancreatic, and lung cancers. CEA levels can provide essential insights into cancer recurrence, response to therapy, and prognosis. It plays a crucial role in detecting cancer at an early stage, allowing for timely intervention and personalized treatment plans. The global CEA market encompasses various diagnostic tests, including CEA assays, kits, reagents, and instrumentation.

Key Drivers of the CEA Market

1. Rising Prevalence of Cancer: The increasing incidence of cancer globally is one of the primary factors driving the CEA market. According to the World Health Organization (WHO), cancer is the second leading cause of death worldwide, accounting for approximately 10 million deaths in 2020. Colorectal cancer, in particular, is among the most common cancers, and CEA is widely used in its diagnosis and management.

2. Advancements in Diagnostic Technologies: Technological advancements in diagnostic tools and techniques have improved the accuracy and efficiency of CEA testing. The introduction of highly sensitive immunoassays, such as enzyme-linked immunosorbent assays (ELISAs) and chemiluminescence immunoassays (CLIAs), has enhanced the ability to detect CEA levels in patients, contributing to better cancer management.

3. Growing Demand for Personalized Medicine: As the healthcare industry shifts towards personalized medicine, the demand for biomarkers like CEA is increasing. CEA testing helps in tailoring treatment strategies based on an individual’s tumor biology and response to therapy, improving treatment outcomes and reducing adverse effects.

4. Increasing Awareness and Government Initiatives: Governments and healthcare organizations worldwide are raising awareness about cancer prevention and early detection. In many countries, cancer screening programs that include CEA testing are being implemented to identify high-risk populations. This has further propelled the demand for CEA diagnostic tests.

Challenges and Restraints

1. Limited Specificity of CEA Testing: One of the primary limitations of CEA as a biomarker is its lack of specificity. Elevated CEA levels can also be observed in non-cancerous conditions such as smoking, liver disease, and inflammatory conditions. This can lead to false-positive results, complicating the diagnostic process. Consequently, CEA testing is often used in conjunction with other diagnostic tools to improve accuracy.

2. High Cost of Advanced Diagnostic Tools: The cost associated with advanced diagnostic technologies, including CEA assays, can be prohibitive for healthcare providers, especially in low- and middle-income countries. This limits the accessibility of CEA testing in certain regions, thereby restricting market growth.

3. Regulatory and Reimbursement Challenges: Regulatory approval processes and reimbursement policies for diagnostic tests vary significantly across regions. Stringent regulations and the absence of uniform reimbursement policies can hinder market growth, particularly for new entrants.

Opportunities in the CEA Market

1. Emerging Markets: Developing countries, particularly in Asia-Pacific, are witnessing a surge in healthcare infrastructure development and cancer awareness programs. These regions present significant opportunities for market expansion as healthcare providers invest in advanced diagnostic tools, including CEA testing.

2. Integration of Artificial Intelligence (AI): The integration of AI and machine learning in diagnostic tools offers promising opportunities for the CEA market. AI-powered algorithms can enhance the interpretation of CEA test results, leading to more accurate and timely diagnoses.

3. Collaboration Between Key Players: Collaborations between pharmaceutical companies, diagnostic laboratories, and research institutions can accelerate the development of innovative CEA tests and assays. Such partnerships can also help in overcoming challenges related to regulatory approvals and market penetration.

Market Segmentation

The CEA market can be segmented based on product type, application, and end-user. Product types include CEA assays, kits, reagents, and instruments. Applications of CEA testing are primarily in colorectal cancer, followed by breast, pancreatic, and lung cancers. Key end-users of CEA testing products are hospitals, diagnostic laboratories, and research institutions.

Competitive Landscape

Several key players dominate the CEA market, including Abbott Laboratories, F. Hoffmann-La Roche AG, Siemens Healthineers, and Thermo Fisher Scientific. These companies focus on product innovation, partnerships, and geographic expansion to maintain a competitive edge. For instance, Roche’s Elecsys CEA assay is a popular product in cancer diagnostics, offering high precision and reliability.

Key Player Analysis:

Abbott (U.S.)

Aviva Systems Biology Corporation

Boster Biological Technology (U.S.)

Cigna (U.S.)

Correlogic Systems, Inc. (Hong Kong)

Creative Diagnostics (U.S.)

Hoffmann-La Roche Ltd (Switzerland)

Genway Biotech, LLC. (U.S.)

Laboratory Corporation of America Holdings (U.S.)

Lee BioSolutions (U.S.)

Mayo Foundation for Medical Education and Research (MFMER) (U.S.)

Merck KGaA (Germany)

Omega Diagnostics Group PLC (U.K.)

Prospec-Tany Technogene Ltd (Israel)

Quest Diagnostics Incorporated (U.S.)

RayBiotech Life, Inc (U.S.)

Segmentation:

By Type,

Serum CEA

Tissue CEA.

By Gender,

Male

Female

By Product,

Kits,

Reagents,

Instruments

By Test,

Clinical testing

Research testing.

By End-Use,

Hospitals,

Diagnostic laboratories,

Research institutes.

By  Region

North America

The U.S

Canada

Mexico

Europe

Germany

France

The U.K.

Italy

Spain

Rest of Europe

Asia Pacific

China

Japan

India

South Korea

South-east Asia

Rest of Asia Pacific

Latin America

Brazil

Argentina

Rest of Latin America

Middle East & Africa

GCC Countries

South Africa

Rest of Middle East and Africa

Browse the full report at https://www.credenceresearch.com/report/carcinoembryonic-antigen-cea-market

About Us:

Credence Research is committed to employee well-being and productivity. Following the COVID-19 pandemic, we have implemented a permanent work-from-home policy for all employees.

Contact:

Credence Research

Please contact us at +91 6232 49 3207

Email: sales@credenceresearch.com

Website: www.credenceresearch.com

[tamanna31]

Blood Screening Market 2023- Business Planning Research and Resources, Revenue, and Forecasts 2030

Blood Screening Market Size & Trends

The global blood screening market size was valued at USD 2.76 billion in 2022 and is anticipated to grow at a compound annual growth rate (CAGR) of 11.7% from 2023 to 2030. 

Blood screening is a process in which donated blood is screened for infectious diseases such as HBV, HCV, HIV1, and HIV2. The high growth of this market is attributed to rising blood donations, an increase in the incidence of infectious diseases, and government initiatives. According to World Health Organization (WHO), 118.54 million blood donations are collected yearly. In the U.S., 6.8 million individuals donate blood annually, and 13.6 million units of red blood cells and whole blood are collected annually.

Gather more insights about the market drivers, restrains and growth of the Blood Screening Market

The market is primarily driven by the rise in the rate of disorders such as HIV, diphtheria, measles and chronic diseases such as hemophilia, cancer, and other blood-related disorders. Blood-based diagnostics are used to diagnose a wide range of diseases, including infectious diseases, cancer, and cardiovascular diseases. Serology tests detect the presence of antibodies to a specific disease-causing organism. These tests diagnose various infectious diseases, including HIV, hepatitis B, and syphilis. Molecular tests detect the presence of DNA or RNA from a specific disease-causing organism. These tests are more sensitive than serology tests and can be used to diagnose diseases at an earlier stage. Biochemical tests measure the levels of certain substances in the blood. These tests can diagnose a wide range of diseases, including diabetes, kidney disease, and liver disease.

The COVID-19 pandemic had a significant impact on the market. Although respiratory droplets are the primary means of COVID-19 virus transmission, research has shown that viral RNA may be discovered in blood samples, supporting blood screening for COVID-19 identification, hence driving the market significantly. 

Blood Screening Market Segmentation

Grand View Research has segmented the global blood screening market based on technology, product, and region:

Technology Outlook (Revenue, USD Million, 2018 - 2030)

Nucleic Acid Amplification Test (NAT)

ELISA

Chemiluminescence Immunoassay (CLIA) and Enzyme Immunoassay (EIA)

Next Generation Sequencing

Western Blotting

Product Outlook (Revenue, USD Million, 2018 - 2030)

Reagent

Instrument

Regional Outlook (Revenue, USD Million, 2018 - 2030)

North America

US

Canada

Europe

UK

Germany

France

Italy

Spain

Sweden

Norway

Denmark

Asia Pacific

Japan

China

India

Australia

Thailand

South Korea

Latin America

Brazil

Mexico

Argentina

Middle East and Africa

Saudi Arabia

South Africa

UAE

Kuwait

Browse through Grand View Research's Medical Devices Industry Research Reports.

The global embolic protection devices market size was valued at USD 612.9 million in 2023 and is projected to grow at a CAGR of 8.7% from 2024 to 2030. 

The global covered stent market size was estimated at USD 1.13 billion in 2023 and is projected to grow at a CAGR of 4.1% from 2024 to 2030. 

Key Companies & Market Share Insights

Product launches, approvals, strategic acquisitions, and innovations are just a few of the important business strategies used by market participants to maintain and grow their global reach.

For instance, in March 2023, Abbott received U.S Food and Drug Administration (FDA) clearance for a laboratory traumatic brain injury blood test, the first commercially available lab-based test for the assessment of mild traumatic brain injuries (TBIs), commonly referred to as concussions, which will be made widely available to hospitals across the U.S. This test, which is powered by Abbott’s Alinity i laboratory tool, will enable clinicians to evaluate individuals with mild traumatic brain injuries in a timely manner.

Furthermore, in May 2023, Siemens Healthcare introduced Atellica HEMA 570 and 580 next-generation hematology analyzers, which have user-friendly interfaces and can be connected to multiple analyzers to remove workflow barriers and provide high throughput time.

Key Blood Screening Companies:

Abbott

Danaher Corporation (Beckman Coulter)

Becton Dickinson and Company

Bio-Rad Laboratories, Inc.

Hoffman-La Roche Ltd.

Grifols, S.A.

Ortho-Clinical Diagnostics, Inc.

Siemens Healthcare GmbH

Thermo Fisher Scientific, Inc.

SOFINA s.a (Biomerieux)

Order a free sample PDF of the Blood Screening Market Intelligence Study, published by Grand View Research. 

[businessindustry]

Chemiluminescence Immunoassay (CLIA) Market Application, Growth 2024-2032

The Reports and Insights, a leading market research company, has recently releases report titled “Chemiluminescence Immunoassay (CLIA) Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2024-2032.” The study provides a detailed analysis of the industry, including the global Chemiluminescence Immunoassay (CLIA) Market Forecast share, size, trends, and growth. The report also includes competitor and regional analysis and highlights the latest advancements in the market.

Report Highlights:

How big is the Chemiluminescence Immunoassay (CLIA) Market?

As per Reports and Insights Analysis, the chemiluminescence immunoassay (CLIA) market is expected to grow at a CAGR of 7.8% during the forecast period of 2024 to 2032.

What are Chemiluminescence Immunoassay (CLIA)?

Chemiluminescence immunoassay (CLIA) is a precise diagnostic method used to detect and measure specific substances, such as proteins, hormones, or antibodies, in a sample. It employs chemiluminescent labels attached to antibodies or antigens that emit light when they bind to their target analytes. This emitted light is quantified using a luminometer, providing a measurement proportional to the concentration of the target substance. CLIA is renowned for its high sensitivity and specificity, making it a valuable tool in clinical diagnostics, research, and various applications in medical and biochemical analysis.

Request for a sample copy with detail analysis: https://www.reportsandinsights.com/sample-request/1671

What are the growth prospects and trends in the Chemiluminescence Immunoassay (CLIA) industry?

The chemiluminescence immunoassay (CLIA) market growth is driven by various factors and trends. The chemiluminescence immunoassay (CLIA) market is experiencing significant growth due to its widespread application in clinical diagnostics and research for accurate detection and quantification of biomarkers. This expansion is fueled by the increasing demand for precise diagnostic tools, advancements in assay technology, and the rising prevalence of chronic diseases. Ongoing innovations in CLIA technology, including the development of new reagents and platforms, are also driving market growth. Leading companies are heavily investing in research and development to improve assay performance and address the evolving needs of the healthcare and research sectors, thereby boosting the overall CLIA market. Hence, all these factors contribute to chemiluminescence immunoassay (CLIA) market growth. 

What is included in market segmentation?

The report has segmented the market into the following categories:

By Product Type:

Analyzers

Reagents & Consumables

By Analyzer Type:

Benchtop Analyzers

Floor-standing Analyzers

By Application:

Infectious Diseases

Oncology

Cardiology

Autoimmune Diseases

Others

By End-Use:

Hospitals & Diagnostic Laboratories

Research & Academic Institutes

Pharmaceutical & Biotechnology Companies

Contract Research Organizations (CROs)

Segmentation By Region:

North America:

United States

Canada

Asia Pacific:

China

India

Japan

Australia & New Zealand

Association of Southeast Asian Nations (ASEAN)

Rest of Asia Pacific

Europe:

Germany

The U.K.

France

Spain

Italy

Russia

Poland

BENELUX (Belgium, the Netherlands, Luxembourg)

NORDIC (Norway, Sweden, Finland, Denmark)

Rest of Europ

Latin America:

Brazil

Mexico

Argentina

Rest of Latin America

The Middle East & Africa:

Saudi Arabia

United Arab Emirates

South Africa

Egypt

Israel

Rest of MEA (Middle East & Africa)

Who are the key players operating in the industry?

The report covers the major market players including:

Roche Diagnostics

Siemens Healthineers

Abbott Laboratories

Beckman Coulter (a subsidiary of Danaher Corporation)

Ortho Clinical Diagnostics

bioMérieux SA

DiaSorin S.p.A.

Sysmex Corporation

Thermo Fisher Scientific Inc.

Mindray Bio-Medical Electronics Co., Ltd.

Randox Laboratories Ltd.

Snibe Diagnostic

View Full Report: https://www.reportsandinsights.com/report/Chemiluminescence Immunoassay (CLIA)-market

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

About Us:

Reports and Insights consistently mееt international benchmarks in the market research industry and maintain a kееn focus on providing only the highest quality of reports and analysis outlooks across markets, industries, domains, sectors, and verticals. We have bееn catering to varying market nееds and do not compromise on quality and research efforts in our objective to deliver only the very best to our clients globally.

Our offerings include comprehensive market intelligence in the form of research reports, production cost reports, feasibility studies, and consulting services. Our team, which includes experienced researchers and analysts from various industries, is dedicated to providing high-quality data and insights to our clientele, ranging from small and medium businesses to Fortune 1000 corporations.

Contact Us:

Reports and Insights Business Research Pvt. Ltd. 1820 Avenue M, Brooklyn, NY, 11230, United States Contact No: +1-(347)-748-1518 Email: sales@reportsandinsights.com Website: https://www.reportsandinsights.com/ Follow us on LinkedIn: https://www.linkedin.com/company/report-and-insights/ Follow us on twitter: https://twitter.com/ReportsandInsi1

[healthcaremarketanalysis]

The report "Blood Screening Market by Product (Reagent & Kits, Instrument, Software), Technology (NAT, (Real-Time PCR), ELISA (Chemiluminescence Immunoassay), Rapid Test, Western Blot), End User (Blood Bank, Hospital), & Region - Global Forecast to 2028", is projected to reach USD 3.4 billion by 2028 from USD 2.4 billion in 2023, at a CAGR of 7.2% during the forecast period. Growth in this market is mainly driven by the growing requirement for donated blood, the rising number of blood donations around the world, and the ever-increasing infectious diseases. However, operational barriers and the high cost of Blood screening instruments is likely to hamper the growth of blood screening market.

[globalgrowthinsights]

Laminated Particle Boards Market Size, Share, Forecast [2032]

Laminated Particle Boards Market provides in-depth analysis of the market state of Laminated Particle Boards manufacturers, including best facts and figures, overview, definition, SWOT analysis, expert opinions, and the most current global developments. The research also calculates market size, price, revenue, cost structure, gross margin, sales, and market share, as well as forecasts and growth rates. The report assists in determining the revenue earned by the selling of this report and technology across different application areas.

Geographically, this report is segmented into several key regions, with sales, revenue, market share and growth Rate of Laminated Particle Boards in these regions till the forecast period

North America

Middle East and Africa

Asia-Pacific

South America

Europe

Key Attentions of Laminated Particle Boards Market Report:

The report offers a comprehensive and broad perspective on the global Laminated Particle Boards Market.

The market statistics represented in different Laminated Particle Boards segments offers complete industry picture.

Market growth drivers, challenges affecting the development of Laminated Particle Boards are analyzed in detail.

The report will help in the analysis of major competitive market scenario, market dynamics of Laminated Particle Boards.

Major stakeholders, key companies Laminated Particle Boards, investment feasibility and new market entrants study is offered.

Development scope of Laminated Particle Boards in each market segment is covered in this report. The macro and micro-economic factors affecting the Laminated Particle Boards Market

Advancement is elaborated in this report. The upstream and downstream components of Laminated Particle Boards and a comprehensive value chain are explained.

Browse More Details On This Report at @https://www.globalgrowthinsights.com/market-reports/laminated-particle-boards-market-100568

 Global Growth Insights

Web: https://www.globalgrowthinsights.com

Our Other Reports:

Global Online MarketMarket Size

Avalanche Airbags MarketMarket Growth

Operating Room Management MarketMarket Analysis

High-Purity Alumina MarketMarket Size

Global Law Enforcement and Military Clothing MarketMarket Share

Global LED Obstruct Lighting MarketMarket Growth

Automatic Chemiluminescence Immunoassay Analyzer MarketMarket

Linear Alkylbenzene Sulfonic Acid MarketMarket Share

Unified Communications as A Service (UCaaS) MarketMarket Growth Rate

3D Models MarketMarket Forecast

Global Freeze Drying MarketMarket Size

Smart Fabrics and Textiles MarketMarket Growth

Zirconia Oxygen Analyzer MarketMarket Analysis

Proteomics MarketMarket Size

Global Social Casino MarketMarket Share

Global Smartwatch MarketMarket Growth

DNA-Encoded Library MarketMarket

Drills MarketMarket Share

Electric Scooter MarketMarket Growth Rate

Agriculture Drones MarketMarket Forecast

Global Transparent and Translucent Concrete MarketMarket Size

Organic Photovoltaics (OPV) MarketMarket Growth

Rolled Annealed Copper Foil MarketMarket Analysis

Anti-Aging Hair Products MarketMarket Size

Global Solid Phase Extraction Apparatus MarketMarket Share

Global Viscose Fiber MarketMarket Growth

Cable Cleats MarketMarket

Gabapentin MarketMarket Share

Offshore Coating MarketMarket Growth Rate

Plastic Bearings MarketMarket Forecast

Global Airport Lounges MarketMarket Size

Postpartum Hemorrhage Treatment Devices MarketMarket Growth

Flower Pots and Planters MarketMarket Analysis

Pharma Contract Manufacturing Organisations (Cmos) for Injectable Drug MarketMarket Size

Global Worsted Yarn MarketMarket Share

Global Angular Velocity Transducers MarketMarket Growth

Engineered Bacterial Cell Protein MarketMarket

Match Boxes MarketMarket Share

Ginseng MarketMarket Growth Rate

Adjustable Intraocular Lens MarketMarket Forecast

[themarketupdate]

Chemiluminescence Immunoassay Market Detailed Strategies, Competitive Landscaping and Developments for next 5 years

Latest added Chemiluminescence Immunoassay Market research study by Archive Market Research offers detailed outlook and elaborates market review till 2030. The market Study is segmented by key regions that are accelerating the marketization. At present, the market players are strategizing and overcoming challenges of current scenario; some of the key players in the study are DiaSorin S.p.A.,Abbott Laboratories,Shenzhen Mindray Bio-Medical Electronics Co., Ltd.,Immunodiagnostic Systems,Siemens Healthineers,Beckman Coulter Inc.,F. Hoffmann-La Roche AG,Inova Diagnostics, Inc.,Maccura Biotechnology Co., Ltd.,Ortho Clinical Diagnostics. etc.  Click for Free Sample Report + All Related Graphs & Charts https://archivemarketresearch.com/report/mice-market-6/sample-report The Chemiluminescence Immunoassay Market size was valued at USD 8.08 billion in 2023 and is projected to reach USD 13.76 billion by 2032, exhibiting a CAGR of 7.9 % during the forecasts period. The latest edition of this report you will be entitled to receive additional chapter / commentary on latest scenario, economic slowdown and COVID-19 impact on overall industry. Further it will also provide qualitative information about when industry could come back on track and what possible measures industry players are taking to deal with current situation. Each of the segment analysis table for forecast period also high % impact on growth. The Global Chemiluminescence Immunoassay segments and Market Data Break Down are illuminated below: {"Product: Consumables",Instruments,"Software & Services"}

Have Any Questions Regarding Global Chemiluminescence Immunoassay Market Report, Ask Our Experts@ https://archivemarketresearch.com/report/mice-market-6/enquiry-before-buy This report will give you an unmistakable perspective on every single reality of the market without a need to allude to some other research report or an information source. Our report will give all of you the realities about the past, present, and eventual fate of the concerned Market. Thanks for reading this article, we can also provide customized report as per company’s specific needs. You can also get separate chapter wise or region wise report versions including North America, Europe or Asia.

More Reports:

https://archivemarketresearch.com/reports/body-fluid-collection-and-diagnostics-market-3871 Contact US : Craig Francis (PR & Marketing Manager) Archive Market Research Unit No. 429, Parsonage Road Edison, NJ New Jersey USA – 08837 Phone: +1 201 565 3262, +44 161 818 8166 sales@advancemarketanalytics.com

[globalinsightsservices]

Esoteric Testing Market to Witness Growth Acceleration During 2021-2033

Market Definition

Esoteric Testing involves the laboratory examination of uncommon molecules and substances that is not often done in a clinical laboratory. These tests are carried out when a doctor needs more comprehensive information regarding the patient’s health. To assess the outcome, a sophisticated device, materials, and specialist are needed.

Market Dynamics

The global esoteric testing market was valued at USD 21.4 billion in 2022 and it is anticipated to grow further up to USD 62.9 billion by 2032, at a CAGR of 11.4% during the forecast period.

To Know More@ https://www.globalinsightservices.com/reports/esoteric-testing-market/

Market Trends and Drivers

The growing geriatric population coupled with the increasing prevalence of chronic and infectious diseases and advancing esoteric DNA sequencing technologies in precision medicine, early diagnosis of cancer, and precision medicine are boosting the growth of the market. Globally, chronic diseases including diabetes, heart disease, and cancer are on the rise. Infectious disease prevalence is also rising at an alarming rate and includes diseases like Dengue, Hepatitis B, C, HIV, Malaria, Tuberculosis, and others. The knowledge of esoteric testing for the quick and accurate detection of certain disorders is growing. Esoteric tests’ improving technology is providing quicker results with improved sensitivity, detection limits, and efficacy. The market is expanding as a result of the rising use of esoteric DNA sequencing, NGS technologies, and whole genome sequencing in the early diagnosis of cancer, precision medicine, and personalized medicine.

Request Sample@ https://www.globalinsightservices.com/request-sample/GIS10283/?utm_id=1017

Research Objectives

Estimates and forecast the overall market size for the total market, across product, service type, type, end-user, and region

Detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling

Identify factors influencing market growth and challenges, opportunities, drivers and restraints

Identify factors that could limit company participation in identified international markets to help properly calibrate market share expectations and growth rates

Trace and evaluate key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities

Thoroughly analyze smaller market segments strategically, focusing on their potential, individual patterns of growth, and impact on the overall market

To thoroughly outline the competitive landscape within the market, including an assessment of business and corporate strategies, aimed at monitoring and dissecting competitive advancements.

Identify the primary market participants, based on their business objectives, regional footprint, product offerings, and strategic initiatives

Request Customization@ https://www.globalinsightservices.com/request-customization/GIS10283/

Global Esoteric Testing Market Segmentation:

By Type

Infectious Diseases Testing

Endocrinology Testing

Oncology Testing

Genetics Testing

Toxicology Testing

Immunology Testing

Neurology Testing

Others

By Technology

Chemiluminescence Immunoassay

Enzyme-Linked Immunosorbent Assay

Mass Spectrometry

Real-Time PCR

DNA Sequencing

Flow Cytometry

Others

By End User

Independent & Reference Laboratories

Hospital Based Technologies

Research Scope

Scope – Highlights, Trends, Insights. Attractiveness, Forecast

Market Sizing – Product Type, End User, Offering Type, Technology, Region, Country, Others

Market Dynamics – Market Segmentation, Demand and Supply, Bargaining Power of Buyers and Sellers, Drivers, Restraints, Opportunities, Threat Analysis, Impact Analysis, Porters 5 Forces, Ansoff Analysis, Supply Chain

Business Framework – Case Studies, Regulatory Landscape, Pricing, Policies and Regulations, New Product Launches. M&As, Recent Developments

Competitive Landscape – Market Share Analysis, Market Leaders, Emerging Players, Vendor Benchmarking, Developmental Strategy Benchmarking, PESTLE Analysis, Value Chain Analysis

Company Profiles – Overview, Business Segments, Business Performance, Product Offering, Key Developmental Strategies, SWOT Analysis.

Buy your copy here@ https://www.globalinsightservices.com/checkout/single_user/GIS10283/

With Global Insight Services, you receive:

10-year forecast to help you make strategic decisions

In-depth segmentation which can be customized as per your requirements

Free consultation with lead analyst of the report

Infographic excel data pack, easy to analyze big data

Robust and transparent research methodology

Unmatched data quality and after sales service

Contact Us:

Global Insight Services LLC 16192, Coastal Highway, Lewes DE 19958 E-mail: info@globalinsightservices.com Phone: +1-833-761-1700 Website: https://www.globalinsightservices.com/

About Global Insight Services:

Global Insight Services (GIS) is a leading multi-industry market research firm headquartered in Delaware, US. We are committed to providing our clients with highest quality data, analysis, and tools to meet all their market research needs. With GIS, you can be assured of the quality of the deliverables, robust & transparent research methodology, and superior service.

[market-insider]

Chemiluminescence Immunoassay Market Insights: Detailed Overview of Market Size, Share, Projected Growth

The global chemiluminescence immunoassay market size is expected to reach USD 15.50 billion by 2030, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 4.6% from 2024 to 2030. The high prevalence of chronic diseases, several advantages of chemiluminescence immunoassay (CLIA) technique, and approval and launch of novel CLIA solutions are anticipated to be the major factors driving the market.

Chemiluminescence Immunoassay Market Report Highlights

Based on product, consumables dominated the market in 2023 owing to their high demand in therapeutic drug monitoring, endocrinology, and disease diagnosis

In terms of application, the infectious disease segment held the largest share in 2023 owing to the high prevalence of such diseases and the launch of novel CLIA assays for infectious disease diagnosis

By end use, in 2020, the hospitals segment accounted for the largest share in 2023 owing to the increasing hospitalizations, along with the rising prevalence of chronic diseases

In North America, the U.S. held the largest share in 2023 owing to the developed healthcare infrastructure, the high adoption of technologically advanced CLIA systems, and the strong geographical presence of prominent players

Asia Pacific is expected to expand at the fastest CAGR during the forecast period. The emergence of local players in developing markets, such as India and China, is primarily driving the regional market

For More Details or Sample Copy please visit link @: Chemiluminescence Immunoassay Market Report

Key players in the market are implementing organic and inorganic growth strategies for the development, launch, and distribution of novel CLIA solutions. For instance, in February 2020, Snibe Diagnostic, a China-based immunoassay manufacturer, received CE marking for its new MAGLUMI 2019-nCoV (SARS-CoV-2) IgM/IgG CLIA kits. In another instance, in January 2018, DiaSorin partnered with Germany-based Qiagen and added Qiagen’s QuantiFERON-TB diagnostic test portfolio to its LIAISON family of fully automated chemiluminescence immunoassay analyzers. Such initiatives by major players are anticipated to significantly support the market growth. However, the high setup cost of automated chemiluminescence immunoassay systems is expected to be a major factor hindering the market growth.

Furthermore, the high prevalence of chronic diseases in key regions and increasing awareness regarding these diseases in emerging economies are anticipated to upsurge the demand for novel diagnostic solutions, including chemiluminescence immunoassay. According to the data published by the American Cancer Society, in 2020, an estimated 1.8 million new cases of cancer were diagnosed in the U.S. and around 606,520 people died due to the disease. In addition, as per the data published by the WHO in November 2020, HIV emerged as a major global public health issue and around 37.9 million people around the globe were living with the disease.

List of major companies in the Chemiluminescence Immunoassay Market

Abbott Laboratories

Beckman Coulter Inc.

DiaSorin S.p.A.

Shenzhen Mindray Bio-Medical Electronics Co., Ltd.

F. Hoffmann-La Roche AG

Siemens Healthineers

Ortho Clinical Diagnostics

For Customized reports or Special Pricing please visit @: Chemiluminescence Immunoassay Market Analysis Report

We have segmented the global chemiluminescence immunoassay market on the basis of product, sample type, application, end-use, and region.